Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06807268 · ClinicalTrials.gov registry record · Phase 3
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
A Phase 3 study of Eczema, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06807268: Recruiting Phase 3 study of Eczema, sponsored by Pfizer.
NCT06807268 is a Phase 3 study of Eczema that is actively recruiting participants, run by Pfizer. The registered enrollment target is 150 participants, below the 201-participant average among 29 other Eczema trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06807268, a Phase 3 study of Eczema, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to \<12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to receive either abrocitinib test medicine or placebo (pretend medicine that looks just like the test medicine) for 16 weeks. The study will last for about 24 weeks in total.
Primary Outcome
The difference in proportion of responders based on vIGA at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Abrocitinib
Study Locations (20)
California
- Investigational Drug Service - Rady Childrens Hospital-San Diego - San Diego
- University of California, San Diego/Rady Children's Hospital-San Diego; Pediatric & Adolescent Derm - San Diego
South Carolina
- Medical University of South Carolina - Charleston
- Tribe Clinical Research, LLC - Greenville
Other
- Shanghai Children's Hospital - Shanghai
- Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine - Shanghai
Alabama
- Cahaba Dermatology & Skin Health Center, LLC - Birmingham
Arkansas
- Arkansas Research Trials - North Little Rock
Florida
- Solutions Through Advanced Research - Jacksonville
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
Missouri
- Saint Louis University - Department of Dermatology - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-07-24 |
| Est. Completion | 2027-05-02 |
| Phase | Phase 3 |
What NCT06807268 shows while recruiting
NCT06807268 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 201-participant average among 29 other Eczema trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Eczema appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06807268 names 20 study sites across 17 states, led by California, South Carolina, Other.
Frequently Asked Questions
What is clinical trial NCT06807268 about?
NCT06807268 is a clinical study titled "A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema". This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to \<12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to re...
What is the current status of trial NCT06807268?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2025-07-24. Estimated completion is 2027-05-02.
What conditions does trial NCT06807268 study?
This clinical trial studies the following conditions: Eczema.
What interventions are being tested in trial NCT06807268?
The interventions under investigation include: Placebo (OTHER), Abrocitinib (DRUG).
Who is sponsoring clinical trial NCT06807268?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06807268 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eczema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06807268's enrollment target sits among peer trials
150 13th of 29 higher than 17 of 29 other Eczema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eczema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema
COMPLETED · Phase 3
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Flourish: Exploring the Early Infant Gut Microbiome
RECRUITING · NA
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI